NHS Net Zero momentum, progressive new NHS initiatives such as NICE’s Early Value Assessment (EVA) programme, domestic reshoring, automation at scale, additive manufacturing, AI‑accelerated sourcing, lifecycle compliance, and practical sustainability set the agenda.

The NHS’s drive to decarbonise supply chains is expected to accelerate UK‑based sourcing as the NHS Net Zero Supplier Roadmap expands requirements around social value weightings and Carbon Reduction Plans, with further product‑level expectations on the horizon. The NICE Early Value Assessment (now part of NICE’s early‑use HealthTech guidance) is designed to enable earlier access to promising technologies addressing unmet needs, with conditional recommendations while further evidence is generated, shortening the path from concept to first clinical use. [england.nhs.uk] [nice.org.uk]

Alongside these policy shifts, 2026 should see automation deployed to deliver high‑volume reliability in disposables, more programmes bridging rapid prototyping to regulated production via additive manufacturing, a step change in AI‑driven sourcing and vendor discovery, and a decisive shift in regulatory and quality expectations towards full lifecycle compliance, balanced with practical sustainability measures that protect patient safety and performance.

Rory O’Keeffe, Commercial Director at Europlaz, said: “2026 looks pivotal for UK medtech. The NHS’s sustainability priorities and EVA’s momentum will favour local, compliant and agile manufacturers. The competitive edge will come from combining automation at scale with rapid design‑transfer and validated materials so we can move faster, and greener.”

The implications for UK procurement, QA and regulatory teams are practical and near term. Shorter supply routes and domestic capacity strengthen resilience for high‑volume disposables while supporting decarbonisation goals. EVA’s structured pathway offers earlier real‑world data alongside ongoing evidence development, enabling managed adoption for technologies addressing unmet needs. To switch suppliers without disruption, manufacturers must demonstrate validated tool transfers, repeatable automation cells and rigorous material verification, underpinned by documentation and change control that maintain continuity across UK and US regulatory pathways. [england.nhs.uk], [nice.org.uk]

Ian Goodacre, Technical Director at Europlaz, added: “Automation isn’t just for complex builds anymore, it’s increasingly about high‑throughput reliability. We’re seeing tangible progress in taking 3D printing into regulated production runs and pushing biopolymer use where it meets performance and sterilisation demands.”

Europlaz notes that regulatory and quality expectations are widening alongside these shifts. Alastair Fry, Regulatory Affairs Manager at Europlaz, commented: “Regulators are looking at the whole journey. We’re strengthening documentation, implementing digital traceability, and conducting packaging, transport and shelf‑life validations, so our customers meet evolving MDR/FDA expectations without delay and with complete audit readiness.”

Richard Buckmaster, Quality Manager at Europlaz, explained: “In 2026, we’ll continue integrating biocompatibility assessments, sterilisation compatibility verification (where applicable) and ISO‑compliant transit validation into core QMS, with end‑to‑end traceability to ensure every device, sterile or non‑sterile, arrives intact and fully compliant.”

On sustainability, Rory emphasised pragmatism: “Sustainability must be practical and safe. We’re piloting bio‑based polymers and increasing recycled content in non‑patient‑contact packaging, but meaningful progress depends on standards and legislation evolving to create space for validated alternatives, unlocking innovation without compromising patient safety or device performance.”

With recruitment costs rising, Europlaz is prioritising retention and internal mobility across its 110‑strong workforce through targeted upskilling of operators and leaders. Funding is in place for up to five industrial placements and five apprenticeships in 2026 to build the skills needed for an automated, digital medtech environment.

Anya Grattidge, Head of HR at Europlaz, said: “Developing the next generation is a priority. Placements and apprenticeships let us grow talent in our culture and scale to meet demand, it’s a practical route more firms should consider.”

• Book a discovery call
• Start a project conversation

Alternatively, below are the industry events we will be attending in 2026. If you’d like to connect and arrange a meeting with the team at any one of these events, contact us.